REGISTERED CHARITY NUMBER: 1143642
Report of the Trustees #Dd
UDaudit¢d Fin4Dei*l Stattments for Iht Ye&r Ended 31 August 2025
for
P$eudoNyKOrn• SMrvfv•r
Harris Lacey and Swain
Suite I
The Riverside Building
H¢551e
East Yorksh￿re
HU13 ODZ

Psevdomyxoma Survivor
Contents of the Fin#neial Stalemellts
for the Year Ended JI August 2025
Page
Report Of the Trll$ttts
Ind¢peDdeDt Eiamin¢r's Report
St*ternent ofFin¥D¢i*l A¢tfvltlt$
Balanct Shttt
Notts to the Finan¢iAI State￿ents
10 to 16

bom￿+
The support network
for those affected by
pseudomyxoma
peritonei. appendix
cancers and rare
peritoneal
malignancies
Registere(t charity 1143642
PSEUDOMYXOMASURVIVOR-ANNUAL REPORTTO 31 AUGUST2025
The trustees present their reportwith the financial statements of the charityfor the year gnded 31 August 2025.
The trustees have adopted the provisions of Accouniing and Reporting by Charities: Statement of
Recommended Practice applicable to charities preparing their accounts in accordance with the Financial
Reporting Standèrd applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191.
OUR OBJECTIVES. AIMS AND ACTIVITIES:
Pseudomyxoma SuNivor's main objectives las set out in the Constitution) are=
To relieve the sickness. mental and emotional distress of those suffering trom pseudomyxoma
Pgritonei IPMPI. their families and Carers.
To provide funds to support research into pseudomyxoma peritonei, its causes. trearment and
cure and to publish the useful results of such research.
To promote awareness of pseudomyxoma peritonei.
Notice of bereavement:
It Ss with deep sorrow that we announced the passing of our esteerned Trustee, Angela Brook in April 2025.
Angela dfyvoted more than twelve years to the leadership and development of P5eudomyxoma SuNivor. and
we were privileged to benefit Irom her unwavering commitment and setvice.
As a palient livingwith pseudomyxoma peritDnei, Angela dedicated hertime and expertise to odvancingthe
charity's mission. She played a pivotal rDle in building and maintaining our website. 8s well as establishing
robust governance systems and procedures essential to the effective management of the charity. Angela's
compassion and insight touched ¢ountless patients and their families. She provided invaluable support to
patients and c8regivers, guiding them through unfamiliar and challenging circumst8nces wr(h empathy and
understanding. Her Leg8cy is one of friendship, resilience. and profound dedicotion to the community she
setvgd.

OURACHIEVEMENT AND PERFORMANCE:
In orderto support our pationt$ and thgir c•rogiv8rs we have provided..
A website providing focussed advice. information and support.
A private Facebookgroup, which ha5 over 1400 members from acro￿ the world. Patients are b8sed in
predominantly Engllsh-speaking countries with members wortdwide.
Practical as well as emotional support to patients and families through our grant programme and h8V8
given financial support to 16 familios this year13 application5 were declined). A total pl £14,500 was
paid.
The ongoing provision of 8 Buddy Scheme to provide one-to-one support to patients and caregivers
around the world.
Access to a family flat in Manchester, to support the families of thos8 patients being tr8at8d 8tThe
Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains
personalised blankets and information about Pseudomyxoma Survivor. Fundingwas provided in
previous years and will be done $0 again as required.
Ward toiletiies to The Christie and Basingstoke.
Support to patient days at both the Christie and Basingstoke hospit81s
In orderto promote awargn088 of p8•udomyxom4 porlionel. Trustees have..
Attended the 14th International CongTess on Peritoneal Surt8ce Malignancies in Lyon, France. The
conference was a joint meeting of the Peritone81 Surface Oncology Group International IPSOGII and the
International Societyfor the Study ot Pleura and Peritoneum IISSPPI and dedicated to improvingthe
treatment and survival of p8riion881 metastases.
Attended various sessions hosted by National Volces. Findacure and data studies
Attended Cancer52 meetings
Promoted Rare Disease Day128th February 20251
Published weekly posts on oli social media channels reg8rding the dise8S0
Supported many competitors and volunteers, by providing merch8ndise for a wide variety of events
Provided specialist leaflets forthe hospitals to hand out to patients.
We have contributed funds to the following resgarch programmes during the year to 31 August 2025..
The team at the Peritoneal Malignancy Institute 81 Basingstoke & North Hampshire Hospitals NHS
Foundalion Trust are undèrtaking a research programme to analyse patient data to craft a machine
188rning predictive modelfor recurrence and survival, to guide clinical decisions and treatment plans.
We are Continuing to monitorthe Norwegian GNAS Vaccine Trial at Oslo University Qslo Un_Lve.r5lty
GNAS r¢sevirchprogiamimc We are delighted to confirm this has now been approved for human patient
trials and the first patient ha5 received their vaccine.
We continue to provide pro-bono support of research trials and studies:
Assistance with an application towards a dietary study in Australi8 etc.

Pseudomyxoma Survivor's purpose and its activititss contribute to the public benelit through activities to
support these objectives. We are here lo help patients understand the treatment options. provide leaflets and
online resources that they can trust. We representthe PMP community through links with other rare disease
charities, by attending conferences and by supporting events organised to raise awareness ofthe disease.
We take pride in the stewardship ol our donations. which we demonstrated through this yearwith our
committed registration with the Fundraising Regulator. Pseudomyxoma Survivor has paid due regard to the
Charity Commission's general guidance on public berielit when reviewing ils aims and objectives and in
planning its future activities.
Charitable actlvities:
Pseudomyxoma is entirely reliant upon donations tor our income and due to ourvery generous supporters. we
have received £124.369 in donations and other income.
We are indebted to 811 of our fundraisers and theirfamilies and friends for their generosity-
Our Facebook support group goes from strength to strength, and we have continued support tor the
pseudomyxoma peritonei community on R8reConneet, 8 Eurordis initiative that provides a multi-lingual
support platform for rare diseases and on the platform opgrated by Cancer Research.
We have continued to develop a close working relationship with the teams at the Basingstoke and North
HampshiTe Hospital and The Christie Hospital in Manchester. which allows us to better support patients, and
identify research opportunities.
Once again we were able to retain our status with the Great Non Profits organisation.
FINANCIAL REVIEW
Financlal position:
We ale extrem&Ly pleased that we have total funds of £257.787 at the end of the fin8n¢ial year. With appropriate
and controlled govèrnance procedures in place, the trustees Goniinue to be confident that gronts and
awareness activities Can increase the value of the charityto the Community.
PseudomyKoma Survivor's incom8 and expenditure is Kelatively small and consequently the charity does not
have suflicient funds to invest in longer term investments such as stocks and shares.
R8ser¥es poticy:
ThrDugh prudence in our activities. we are now able to en$ureth8t we have a reserve in future years. We will do
this through our plan which ensures the charity has feserves to cover our patient grant scheme, basic
resources required to keep us 'in business, and to attend conlerences where we can represent the voice of the
PMP community goingforward. for 24 monlhs. With appropriate and controlled governance proeedures in
place. the trustees continue to bts confident that grants and awareness activities can incr8ase the value of the
charity to the community.
Duringthe yearto 31 August 2025. 12 months, expenditure eqv8ted to £31,931. plus the expenditure on
research of £36.000 and family grants of £14,500, tot8lling £82.431. Whereas reserves at the pèriod end
totalled £257,787 and reserves excluding designated funds totalled £121,287.
We have designated expenditure as at the year ended 31 August 2025 of £136,50012024-. £79,0981 which will be
spent in accordance with our ch8rit8ble objectives. aims and aetiwlies which are detailed in the Trusiee
Report. All oppc>rtunities will be scrutinised in accordance with our due diligence procedures before any
expenditure is committed.

Future plan8:
With very grateful thanks to our very generous donors, we have plans in place to fi'nancially support the
foiiowin8 initiatives during the financialyear 202512026..
The ongoing provision of family and caiegivers accommodation at the Christi& Hospital in Manchester.
We will continue to promote the Family Grants to give financial support where appropriate.
We will continue to monitor th& team at th8 B8singstoke Hospital on the Tesearch programme which
aims to analyse patient data to craft a m8¢hine learning predictive model for recurrence and survival, to
guide clinical decisions and treatment plans.
The team at the Christie Hospital in Manchester are in very early stage discussions with us regBrding a
new research project for which funding of £100,000 May be requested.
We will have discussions with the Christie Hospital in Manchester to continue to monitor and suppon
the prehabilitation study.
We will kggp in touch with ail of our patients and caregivers especially when we know that they are
going through stressful srtuations.
We will continue to closely monitorthe NonMegiBn GNAS research programme, which has now been
approvBd and ent8r8d inio patienttrials.

P$¢udom￿0M1 Survivor
Rep)rt of the Tru$tces
for the YtAr Ended JI Augusl Z025
STRucfuRE, GOVERNANCE AIYD MANAGEMENT
CoverniDg documtni
The charity is controlled by L15 governing document, a d¢d of irusl constitutes an urtittcorporaied charity.
Rtcruitmtnt lppointmtllt of new trustets
Trustees are appointed by th¢ ¢xisting trustee5. We are delighted thai Madeleine Lomas has bttn appointed a Trustee
with etyect 23 Jun¢ 2025.
Oryalli$itloA*l structsre
In addition to the Trustees we havc a group of voluntccrs who activcly undcrtake the day to day administration of the
FaCe￿0k group and a fvrthcr 60 who volunicer &$ Buddys on the Buddy schetne.
Our people
Pseudomyxoma Survivor relies entirely on the d¢dication of volunteers lo deliveT and manage the activities of our
charity, We are fortwlaie to hav¢ fJv¢ aetive Tr￿glet5. each bringing a wealth of 5kn11s and ¢XFeri¢nre that will help us
grow and thrive in th¢ y¢ar5 ahead. Th¢iT COll)ffiitin¢nt and generosily in giving their time to SUP￿r( th¢ Charity is
invaluablc.
W¢ would also like to exiend our heart￿11 thanks 10 all of our volunieers this fir￿￿la1 year, particulaTly Ihtyse who
moderat¢ the Patient group and manage the buddie5 sch¢m¢.
A special acknowled￿ent goes io Mark Pon5ford. who l¢d gn online patieni discussion torum every week since
2018. This retnarkable level of commitmeni 10 th¢ ihariiy and io fellow patients is deeply 3ppr¢riated.
REFERENCE AND ADMINISTRATIVE DETAIts
Registtrtd Charity number
1143642
Principal ¥ddre$$
Appleir¢¢ House
Mill Lane. Ellerlo
York
Y042 4PA
TThstetS
Mrs S Oliver
Mr T Brill
Mrs C Fletcher
Mrs A C Salisbury
Mrs A B Brook Ideceased 2.4.251
Ms M C Lorllas {appoinied 23.6.251
llldependent Ex4mither
Harris Lacey and Swain
Suite I
The Riverside Building
He551¢
East Yorkshire
HU13 ODZ
Page 5

Pstydomyxoma Surviv(pr
Report of the Tru5tee5
for thé Yexr Ended 31 Augllst 2025
Approv¢d by order of the board of trus￿eS on.....30 December 2025 and signed on its behalf by-
tr-JJ
Mrs A C Salisbwy- Ttuske
Page 6

llldeptttdent Eximtner's Report to the Trustees of
Pseudomyxom¥ Survivor
Ihd*pendeht t%#￿iller'S report to tht trustees of Pseudrlmyxoma Survivor
l Tey)rt to the charity IfLislees on my examination ot. the accounts of P5¢udOin￿orna Surviv¢r (the T￿￿1) for the ￿ar
etKled 31 AllE￿$t 2025.
Respon5ibilitie5 and b¥si5 of report
As the charity trLJsiees of the TrLLSt you are resporsible for the preparation of the ac¢ounts in arth)rd#n¢¢ with the
requirements of th¢ Charitl¢5 AGt 201 I Ilhe Aci'l.
J repon in respect of rtly exam1r￿tIOn tsf the Trust's accounts ¢arTied out under Section 145 ofihe Aci and in carrying o
my examination I have followed all applicabl¢ Direction5 given by ihe Charity Cotnmi55ion under Section 14515Xbl of
the Act.
JndepeJdent exarniner's statsment
I have completed my examittaiion. J Lonfimi Ih8t no material matters hav¢ come io my attention in conn¢clion with th¢
examinaiion gi¥in8 me cause to believe that in any material respect..
accounting records were not kept in respect of th¢ Trust as requir¢d by Section 130 of the Aci., or
tk accDunts do nDt accord with thos¢ rccords," or
the accounts do not cornply with th¢ applicable requiretnents conreming the totm and tonteni of accounis set out
ir) the Charitie5 IAcLounts atkl Reports) Re%￿atiOnS 2008 other than any req112r¢ment that the accounts give
true and fair vi¢w which is noi a matter considered as part of an indyndenl exaTnI[￿1i0n.
I have no concerns and have corne across no oth¢T inatters in conn¢¢tion with the examination to which attention should
be drawn in ihis rewirt in order to enable a proper understanding of the acwunts to bc TeJchcd.
Laur8 Drew
HaTris La¢¢y ond Swain
Suit¢ I
The RiveTside Building
Hessle
EA$t YoTkshire
HU13 ODZ
Dai¢..
Page 7

PstudomyXo￿1 Survlvor
Sigtem¢nt of Finanf IAI Aitivitie5
for the YtAr Endtd 31 August 2015
2025
Total
funds
2024
Total
fi￿d5
Unresiricied
nds
Restricted
funds
Noies
INCOME AND ENDOWMENTS FROM
Donations and legacies
124).IKII
1,895
121,896
64.216
Investment income
2,473
2,473
Total
122.474
1,89>
124.369
64,216
EXPENDITURE ON
Raising fijnds
9,648
9.648
9,293
Ch*rltabl* #ttlvltlts
Charitable aitivit¢5
Grant making
Support Costs
19,883
14,655
1.920
19,883
50,980
1.920
12.621
53,513
.830
36,325
Tot#1
46,106
36,325
82,431
77.257
NET INCOMFJIEXPENDrrvRE)
76.368
128,9551
134.4301
28,955
41,938
113,041)
TrAtssfers bttwttn funds
12
Net movtmttht itt funds
J17,4l3
li,47il
41,938
113.041}
RECONCILIATION OF FUNDS
Totsl ￿ndS brought forward
210,374
5.475
215.849
228.890
TOTAL FUNDS CARRIED FORWARI)
257,787
257.787
215.849
The notes form part of these financial siaicmcnis
Page 8

P5eudomyxotn4 Survivor
¥I¥nce Sh￿t
31 August 2025
2025
Total
funds
2024
Total
fvnds
Unre$tiieied
funds
ResiTiclcd
fvnds
Notes
CURRENT ASSETS
Debtors
Cash at bank
10
1.172
?58.535
1.172
258,535
1,993
217,382
259.707
259,707
219,375
CREDITORS
Arnounis fallin8 due within one year
(1,9201
11,9201
13,5261
NET CURRENT ASSETS
257,787
257.787
215,849
TOTAL Assrfs LESS CURRENT
LIABILITIES
257.787
257,787
215.849
NET ASSETS
257,787
257,787
215,849
FUNDS
12
Unrestricted funds
Re5tricl¢d funds
257,787
210,374
5.475
TOTAL FUNDS
257,787
215.849
The flnancial staiemenis were approved by the Board ot TTUSlttS and authoriscd for issue
..30 Dcc¢mkr 2025.... and w¢r¢ signed on ils behalf by..
on
Fr-A.J._
Mrs A C Salisbury- TIiL%t¢e
The rrf)les form part of these fJnancia] giatcmcnts
Page 9

P$eudomyxotth* Sllrvfvor
Notes to the Financial Staternents
for the YtXT Ended 31 August 2025
ACCOUNTING POLICIES
Blsis of prepxTirtg the fillxnei*l statements
The tinanrial 5t>ternenlS of the charity. which 1$ a public benefit emiity und¢T FRS 102. have been prepared in
ac¢ordanLe wilh the Chariiies SORP IFRS 1021 'Accounting and ReFK>rtlDg by Cknril2e$.. Stsiern¢nt of
Recomjnended Practice applicable to LharitlLS prcparing IhciT aecounls in accordance with the Financial
Reporting Standard applicable In Ihc UK and Rcpublic of Ireland IFRS 1021 (effective l January 20191..
Financial Reporting Standard 102 'The Financial Re￿rtIng Standard applicable in the UK and Republic of
Ireland. and the Charities ALI 2011. The financial siatements hav¢ been pr¢par¢d un(kr the tlislorical cost
convention.
ID¢ome
Income r¢ceived for seryites provided is accounted for on an accruals basis.
Cash donalivns, gilts and legacies are included in full in t]ie income and expenditure account ￿ tILey are
receiv¢d. Any si￿￿rIcant non￿ donation5 3r¢ included in the income and expendiiurc account at the Iiustees,
cstitnai¢ of their rnarket vttlue when received. The value of voluniary klp is not included in the accoun13.
Grhnts and other fundin8 of a revenue naiure are deferred and relea5¢d lo the inwme and exp¢nditur¢ account
over th¢ period to which they relate.
Bank interest is includd in the incotne and expertditure account on an accruals b&8iS.
Expenditure
Liabililieb are Tetognised as expenditure as 500n a5 Ihere is a legaj or con51rvclive obligation cgmmitting the
charity to Ihar ¢xp¢nditure, it is probabl¢ that a transfer of cconotnic bcn¢tiis will be requirtd in senlemeni and
Ihc amount of Ihc obligaiion can b¢ rn¢asured reliably. ExptndiiuTe is a¢¢ounted for on art a¢eruals basis and h
en cla55ifi¢d und¢r headirw that Yggregaie all cosi related 10 ihe category. Where costs canNt be dir¢cily
atlributcd to particular headings they have be￿ aJlocat¢d to activities on a basis consi8rcnl with the use of
resource5.
Grknis offered subjeet to COtLdiiions which havt noi b¢¢n mer ai the end date are noted a5 a cornmitm¢nt but
rM)t accrued as exF¢nditure.
Taxation
Thc ch￿lty L5 ¢x¢ri)pt frotn on its charitable aciiviiies.
Fu4d accountin¥
UnrestFict¢d lunds can b¢ used in accordance wilh the chJritabl¢ objective$ at the discretion of the Iruslees.
Restricied tunds can only be uKd for parUcul?r restricted purposes wiihin the objecis o(Ihe charity. Resiriction5
rise when sp¢cifi¢d by the donor OT when lun(L% are iaised for pariicular restricted purposes.
Further ￿planation of the tL4iure and putpose of each filnd is incIL￿ed in ihe tLOi¢S to th¢ finaticial 5tal¢m¢tLts.
Estimates and judgemtnts
Esiirnat¢s a[￿ jud8etnenlS ate continually evaluated and are based on historical expcriencc and other factors,
including CXPCClalions of future cvents that are b¢li¢v¢d to b¢ r¢asonable under Ihe cir¢umsiances. Although
thes¢ estimates are based On the DirettOT$' besi knowledge of the amouni. events or a¢t10t￿ actual T¢suIts
ultimdlely dirrer from ¢l￿e esiinutts. The Dir¢ctor5 do not consider there to bc any maierial estimates and
judgements.
Pag¢ 10
Continued...

P5eudomyxomi STAryivor
Note5 to the Fithxtt¢ial Stxttme#t$- tontinued
f4Jr the Year Ended JI August 2025
ACCOUNTING POLICILS- tontittued
Fin*ncial iDStruments
Thc compan>. only ha5 financial assets and financial liabilities of a kind that qU￿lfy as basic fLn8ncial
instruments. Ba55c financial in5trutnetLlS, including trade and other debtors and ¢￿dItOrs. are initially recognis¢d
ai IransaLiion valu¢ and subs¢qu¢ntly m¢a5ured at their 5eiilern¢nt value.
INVFSTMENT INCOME
2025
2024
Deposit account interest
2.473
RAISING FUNDS
Raising donations xnd leiacies
2025
2024
j￿81 Giying
Costs of generating fillid5
2,173
7.475
1,325
7,968
9,648
9,293
CHAR￿ABLE AcfivITIES COSTS
Grani
fundin8 of
Support
COSt51see
note 6)
Direct
Costs
Isc¢ noi¢
51
Totals
Charitsble activites
Grant making
Support costs
19.883
19,883
50.980
1,920
50.980
.920
19.883
50.980
1,920
72,783
GK4NTS PAYABLE
2025
2024
Grant n￿knn8
50,980
53,513
The li)1￿ grants paid to inslituiions during the year %v4s as follows..
2025
2024
Granis given
36.QO
46,000
A grani totallin8 £36.000 wa8 awarded to The PeTitQDeal Malignancy Insiiiuie ai Basingsioke Hospiial towards
r¢5¢arch to an#lys¢ patient data to craft a Machine Learning pr¢dicliv¢ fflod¢l for recutrence and survival. to
guide ¢liniLal decisions and ir¢aimeni plan5.
P8g¢ 11
Continued...

Pseudomyxoma Survivor
Note5 to the Fin4Dcial StatemEntS- Cotttithtted
lor the Year EDdtd 31 Augu512025
SUPPORT COSTS
Gov¢rnance
COSts
Support costs
1,920
Support costs, included in the above. are as follow5.'
2025
Support
costs
2024
Total
activities
Independent cxaminalion
1.920
1,830
TRUSTEES, REMUNERATION AND BENEFITS
Ther¢ was tr￿tte$. remunerattotj iotalling £9,000 12024 - £8,820) bui no other benefits for th¢ year ¢rKied 31
August 2025 or oiher benefiis for tlie year ¢nd¢d 31 Augvst 2024.
The remuncraiion received by Mrs S Oliver for their Tole as the Ch&rity's administraior, after much
constdevdtion by the board as to how ￿ fjll this role. This was recordd in the Charity's ly)ard tneeting rninules.
Tru5te¢s' txpensts
There were no
31 August 2024.
ITltslttS' expenses paid for the year ended 31 August 202) nor for th¢ year ended
STAFF COSTS
There w¢r¢ JKk siaff Costs f(PT th¢ year ended 31 August 2025 nor for the year ended 31 August 2024.
The av¢rug¢ numkr of employee5 durin% the year NIL12024- NIL).
No employees received emoluments in exeess of £60,000.
COMPAIL4TIVES FOR THE STATEMENT OF FINANCIAL ACTlVtriES
UnrestTiCted
nds
Restricted
funds
Toial
turyJ5
INCOME AND ENDOWMENTS FROM
Dvnalions legacies
58,741
5,475
64,216
EXPENDITURE ON
Raising fvrKi8
9,293
9,293
Charitable *¢dvlik$
Charitable aciivilcs
Grant makang
Stspp)rt costs
12,621
22.513
1,830
12,621
53.513
1,830
31.000
Total
46,257
31,000
77.257
NET INCOMEIIEXPENDITUREI
12,484
(25,525)
113,0411
Page 12
oniinued...

P5eudomy¥oma SwrvivoT
Notts to the FinaAcial St3ttments- tontlAued
for th¢ Year Ended 31 August 2025
COMPARATIVES FOR THE &fATEMENT OF FINANCIAL ACTIVITIES- continu¢d
Unresiricied
fund5
Restricted
fvnds
Total
fund5
Tr*kn$ftrs bttwttn funds
131.0001
31,000
Net movernent in funds
5,475
{13.041}
RECONCILIATION OF FUNDS
Total funds broughi forward
228.890
228,890
TOTAL FUNDS CARIUED FORWARD
210,374
5.475
215.849
10.
DEBTORS.. AMOUIYTS FALLING DUE WITHIN ONE YEAR
2025
2024
Oiher debiors
Prepayments and accrued income
,025
147
1,846
147
1.172
1,993
ii.
cRED￿ORS. Amoupffs FALLINC DUE WITHIN ONE YEAR
2025
2024
Trade ctediiors
Other crediiors
1,696
1.830
1,920
1,920
3.526
12.
MOVEMENT IN Fuf+4DS
Nei
tnovejnenl
in funds
Transfers
between
fijnds
At 1.9.24
31.8.25
Unre5trieted funds
Gtncral fund
Designated fund
131,276
79,098
76,368
186,3571
57,402
121,287
136.500
210,374
76,368
128,9551
257,787
Re5trirted funds
Research fund
5,475
134,4301
28,955
TOTAL FUNDS
215.849
41,938
257.787
Page 13
conliDued..

Pseudomyxoma Survhvor
Notes to the FinHn¢ial Staternent5- continued
for the Year Ended 31 August 2025
12.
MOVEMENT IIY FUNDS- continued
Ncl movement in funds, included in the aknv¢ are as follows..
Incotning
resources
R¢50urce5
expended
Movern¢tLt
in fvnds
Unrestricted fuTrd5
Geneial fund
122.474
146,1061
76,368
Restricted funds
Research fund
Family grants
1,570
325
(36.0001
{34,4301
.895
136.325}
134,4301
TOTAL FUNDS
124.369
{82,4311
41,938
Comparatives for Jnovement in fulbds
Transfer5
b¢tween
ovemeDI
in funds
At
31.8.24
Ai 1.9.?3
Unr¢strict¢d funds
GeneTal fund
Iksign&ted fund
111.390
117,500
12,484
7,402
138,4021
131,276
79.098
228,890
12.484
131,000)
210,374
Restricted funds
Research fund
125,5251
31,000
5,475
TOTAL FUNDS
228,890
113,0411
215,849
Comparative n¢t Jnovement in funds. included in the above are as follows..
Incoming
resources
RegouTttS
expended
Movetllent
in ￿ndS
Unrestricted fuxd8
General fund
58.741
(46,2571
12,484
Restricted funds
R¢s¢ar¢h fvnd
5,475
131,000)
125,5251
TOTAL FUNDS
64.?16
177.2571
Ili.0411
Page 14
continued...

Pseudomyxoma su￿1￿or
Notts to tht Finan¢i*l StAtementS- ¢Olltittued
for tht Year Ended 31 August 2025
12.
MOVEMEfff IN FUNDS- tootinutd
A current year 12 Monti￿ and prior year 12 months wmbined position is &$ follows..
Nei
movement
in fun&
Trnnsfers
between
tiind5
At 1.9.23
31.8.25
UnT¢5tricted fund$
General fund
Designated fund
111.390
117,500
88,852
178,9551
19.000
121,287
136.500
228,890
88.852
159.9551
257,787
Rcstrttttd funds
Research fvnd
159.9551
59,955
TOTAL FUNDS
228,890
28,897
257.787
A current year 12 months and prior year 12 Tnonths Co￿bIned Det mQV¢Tnent in fvrtds, included in thc ab)vc are
as follows:
Jncoming
resources
ReSQUT¢¢5
expended
Movetnent
in funds
Unrestricted fuuds
General fund
181,215
(92.3631
88,852
Restrirted furtds
Research fund
Ftmily grartts
7,045
325
167.000)
13251
159,9551
7,370
167.3251
159,9551
TixfAL FUNDS
188.585
1159,688}
28,897
Re5trict¢d fvnd5 r¢late ￿ the provision of Ttst2rch funding.
Transftrj bttwetn fuids
Fund transfers during the y¢aT relate to th¢ tTattsfer5 of previously dcsi8Aated tiinds to cover actual spending in
the year.
The desi8rta(cd fund relates 10 monies ser aside for committed future spending.
Page 15
coijtinu¢d...

P5tudomyxoma Survivor
Note5 to the FiDiIDci￿l St*tethents- contiNutd
for the Ytar Ended JI August 2025
13.
RELATED PARTY DISCLOSURES
There w¢r¢ no related party transactions for the year ended 31 Augusi 2025.
Page 16